Drug intelligence / Profile preview

RESP3000

Development stage
Preclinical
Lead developer
Respiratorius
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

RESP3000 is a preclinical-stage radiopharmaceutical PET (Positron Emission Tomography) imaging agent developed by Respiratorius for cardiovascular diagnostics. It is specifically designed for myocardial perfusion imaging (MPI) to detect coronary artery disease. The agent is a small molecule tracer, typically labeled with fluorine-18 (18F), that binds to mitochondrial complex I in the myocardium. By utilizing PET technology, RESP3000 aims to provide superior image resolution, improved sensitivity, and more accurate quantification of myocardial blood flow compared to traditional technetium-99m-based SPECT (Single Photon Emission Computed Tomography) imaging. The use of fluorine-18 allows for a longer half-life than other PET tracers like rubidium-82, facilitating centralized distribution to medical centers.

02

Targets

NADH:ubiquinone oxidoreductase subunit family

Beyond the preview

Go deeper on RESP3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RESP3000.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call